Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration.
about
Eryptosis as a marker of Parkinson's diseaseSafety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease.Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy.[Pharmacological treatment of motor symptoms in Parkinson's diseases].Levodopa-Carbidopa Intestinal Gel in a Pediatric Parkinsonism-plus Syndrome
P2860
Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration.
@en
type
label
Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration.
@en
prefLabel
Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration.
@en
P2860
P1476
Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration.
@en
P2093
Wolfgang H Jost
P2860
P304
P356
10.1517/14740338.2014.896336
P407
P577
2014-03-10T00:00:00Z